KalVista Pharmaceuticals 

KalVista Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical firm dedicated to the discovery, development, and commercialization of small molecule protease inhibitors. These inhibitors aim to address diseases with significant unmet medical needs. The company's core therapeutic strategy centers on its pipeline of small molecule plasma kallikrein inhibitors. These are specifically engineered to combat debilitating conditions such as hereditary angioedema (HAE) and diabetic macular edema (DME), with several formulated as oral treatments. Key products in their portfolio include: KVD001, a plasma kallikrein inhibitor that has successfully concluded a Phase II clinical trial for the treatment of DME. Sebetralstat, which is currently advancing into the Phase 3 KONFIDENT trial, poised to become an oral, on-demand therapeutic option for acute HAE attacks. KVD824, another oral candidate in development for the management of HAE. A Factor XIIa oral inhibitor program, which is in its preclinical stage, targeting a specific enzyme implicated in HAE. The company's main offices are located in Cambridge, Massachusetts.